Precision Oncology as a Model for Bridging the “Valley of Death”

A persistent challenge in anti-cancer drug development remains translation from animal studies to human clinical trials. A shocking 57% of late-stage oncology trials fail due to inadequate efficacy. These failures amount to billions of dollars in...

Read More

Certis Oncology Offers Translational Science Services to Pharmaceutical Industry, Welcomes New BUsiness Development Leader

San Diego, CA – Certis Oncology Solutions, a precision oncology and translational sciences company, announced it will make available its personalized approach to drug efficacy testing to the commercial pharmaceutical industry. Industry veteran...

Read More

Orthotopic PDX: The Gold Standard in Precision Oncology

On December 15th, 2020, Dr. Jonathan Nakashima, PhD, CSO of Certis Oncology, joined Taconic Biosciences to present a comprehensive overview of O-PDX testing. O-PDX is a technique which uses in vivo pharmacology testing in personalized mouse models,...

Read More

Certis Teams Up With Mainly Mozart To Keep The Music Playing

“The best way to get everyone back to living a full life — including enjoying live performances — is through more and more accurate testing,” Peter Ellman, CEO of Certis Oncology Solutions, said in a statement. “We applaud Mainly Mozart for finding...

Read More

Certis Oncology Solutions Announces Mobile Covid-19 Testing

San Diego, CA – Certis Oncology Solutions, a clinical research organization (CRO) and precision cancer therapy company, announced today it is offering mobile COVID-19 testing services to area businesses.“We felt compelled to pitch in,” said Peter...

Read More